Is First Patient Dosed Altering The Investment Case For Janux Therapeutics (JANX)?
Janux Therapeutics has dosed its first patient in a Phase 1 study combining JANX013 and JANX007 for metastatic castration-resistant prostate cancer, marking a key step for its precision oncology platform. This clinical trial broadens the company's prostate cancer franchise and is an execution test for its high-risk, high-spend R&D strategy, influencing its investment narrative which currently shows projected revenue growth alongside declining forecast earnings. Investors are watching trial progress, partnership milestones, and cash management for this clinical-stage biotech.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 clinical trial for JANX013. This novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific is designed to enhance anti-tumor immune responses, particularly when combined with Janux's existing PSMA-targeted T cell engager candidates like JANX007, for patients with metastatic castration-resistant prostate cancer (mCRPC). The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013, with the goal of improving long-term outcomes for prostate cancer patients through tumor-restricted CD28 co-stimulation.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 clinical trial for JANX013, a novel PSMA-targeted, tumor-activated CD28 co-stimulatory bispecific. This therapy aims to enhance anti-tumor immune responses, particularly in combination with Janux's T-cell engager candidates like JANX007, for patients with metastatic castration-resistant prostate cancer (mCRPC). The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013.
Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate
Janux Therapeutics has dosed the first participant in its Phase 1 study for a prostate cancer candidate. The company, a clinical-stage biopharmaceutical firm, is developing tumor-activated immunotherapies and has multiple bispecific platforms. This new study highlights their ongoing efforts in targeting various cancers with innovative treatments.
Price-Driven Insight from (JANX) for Rule-Based Strategy
This article provides a price-driven analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating a near-term weak sentiment within a broader long-term weak bias, despite mid-term strength. It highlights a mid-channel oscillation pattern and an exceptional short setup with a 107.6:1 risk-reward ratio. The analysis presents institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels.
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23
Wolfe Research has initiated coverage on Janux Therapeutics (JANX.US) with a Buy rating. The firm has set a price target of $23 for the company's shares. This initiation suggests a positive outlook from Wolfe Research regarding Janux Therapeutics' future performance.
Wolfe Research upgrades Janux stock rating on autoimmune data
Wolfe Research upgraded Janux Therapeutics shares from Peerperform to Outperform with a $23 price target, citing upcoming autoimmune data as a key catalyst. The stock has shown volatility and is considered undervalued by InvestingPro. Janux also recently announced the departure of its Chief Medical Officer, William Go, and is actively seeking a replacement.
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile?
Janux Therapeutics (JANX) reported reduced net losses and lower basic loss per share for Q2 and the first six months of 2026, indicating more efficient cost management. While this eases near-term financing concerns for the pre-profit biotech, its investment narrative still hinges on the success of its TRACTr and ARM platforms, clinical trial data, and the Bristol Myers Squibb partnership. The company faces significant risks related to trial outcomes, cash burn, potential dilution, and a potentially inflated share price compared to its estimated value.
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux Therapeutics (JANX) shares have increased by 19.1% over the past three months and 25.3% year-to-date, driven by advancements in its oncology and autoimmune pipelines. Key developments include progress in prostate cancer candidate JANX007 and the launch of autoimmune candidate JANX011. The company also maintains strategic collaborations with Merck & Co. and Bristol Myers Squibb and boasts a strong balance sheet with $970.9 million in cash.
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile?
Janux Therapeutics (JANX) reported reduced net losses of US$21.97 million for Q2 2026 and US$46.33 million for the six-month period, indicating more efficient cost management. While these narrowing losses ease near-term financing concerns, Janux remains a pre-profit, high-spend biotech company heavily reliant on future clinical trial outcomes and its partnership with Bristol Myers Squibb. Investors are advised to consider the company's valuation report, which suggests an inflated share price compared to its estimated value.
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Janux Therapeutics (NASDAQ:JANX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $37.58, despite some recent price target reductions. The company's stock opened at $17.52 with a market capitalization of $1.07 billion, and its latest quarterly results missed analyst expectations for both EPS and revenue. Institutional investors hold a significant 75.39% stake in Janux Therapeutics, a clinical-stage biotechnology company focused on immuno-oncology therapies.
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA)
This article provides analyst insights for two healthcare companies, Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA). William Blair analyst Matt Phipps maintained a Buy rating for Janux Therapeutics Inc, while William Blair analyst Jared Haase maintained a Sell rating for Ginkgo Bioworks Holdings. The article details analyst consensus, price targets, and recent stock performance for both companies.
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX
Dimensional Fund Advisors LP significantly reduced its stake in Janux Therapeutics, Inc. by 56.9% in the first quarter, now holding 96,630 shares valued at approximately $1.34 million. Despite Janux Therapeutics missing consensus estimates for its recent quarterly earnings and revenue, institutional investors collectively own 75.39% of the company's stock. Analysts currently rate JANX as a "Moderate Buy" with a consensus price target of $37.58, which is substantially higher than its recent trading price of $16.12.
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund
Point72 Asset Management and its related entities, including Point72 Capital Advisors, Inc. and Steven A. Cohen, have reported a beneficial ownership of 1,993,837 shares of Janux Therapeutics (JANX) common stock, representing 3.3% of the outstanding class as of June 30, 2026. This stake is held through investment funds managed by Point72, with shared voting and dispositive power among the reporting persons. The filing, a Schedule 13G/A, indicates that the ownership is below 5% and is for passive investment purposes.
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management
Janus Henderson Group Ltd. has reported beneficial ownership of 172,229 shares of Janux Therapeutics, Inc. common stock, which represents a 0.3% stake in the company. These shares are held across various client accounts managed by Janus Henderson's investment adviser subsidiaries, and the group exercises shared voting and dispositive power over them. The filing clarifies that the dividends and sale proceeds from these shares accrue to the Managed Portfolios, not Janus Henderson directly, and no single Managed Portfolio holds more than five percent of Janux Therapeutics' common stock.
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35
Stifel has reiterated its Buy rating for Janux Therapeutics (JANX.US) and maintained its target price at $35. This indicates a continued positive outlook from the investment firm regarding the company's stock performance.
The Janux Therapeutics, Inc. (NASDAQ:JANX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Janux Therapeutics reported its second-quarter results, showing significant revenue growth from collaborations and a substantial cash reserve. Analysts have updated their forecasts, maintaining a "buy" consensus with a new average price target of US$47.90, indicating a potential 30% upside from the current share price. The company's financial health appears strong, supported by its cash position and ongoing R&D investments.
Equities Analysts Set Expectations for JANX Q3 Earnings
HC Wainwright has revised its Q3 2026 EPS estimate for Janux Therapeutics (NASDAQ:JANX) to a loss of $0.45 per share, an improvement from its previous estimate. Despite this, Janux Therapeutics recently reported quarterly earnings that fell short of expectations, with an EPS loss of $0.35 against an estimated $0.25 loss and lower-than-expected revenue. The company maintains a "Moderate Buy" analyst rating with an average price target of $37.58, while institutional investors hold a significant 75.39% stake in the stock.
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings
HC Wainwright has lowered its FY2030 earnings per share (EPS) estimate for Janux Therapeutics (NASDAQ:JANX) to $0.97, down from $1.06, while the consensus remains a loss of $1.70 per share. This adjustment follows Janux's recent quarterly earnings report, where the company missed analyst expectations with a loss of $0.35 per share and revenue of $10.27 million against an anticipated $19.07 million. Despite the lowered forecast and recent price target reductions from other analysts, Janux Therapeutics still holds a "Moderate Buy" consensus rating with an average target price significantly higher than its current share price.
Janux Therapeutics Inc (JANX) Stock News Today
This article provides an overview of Janux Therapeutics Inc (JANX) stock information, including its current trading price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the platform for users interested in the company.
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile
Janux Therapeutics (JANX) saw its stock rise by 7.1% after announcing a narrower net loss for the second quarter and first half of 2026. The company reported a net loss of US$21.97 million, or US$0.35 per share, in Q2 2026, an improvement from US$33.86 million, or US$0.55 per share, a year prior. While this indicates better cost control, the article notes that funding needs and dilution risk remain key concerns for investors due to the company's high valuation multiples and ongoing unprofitability.
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating
RBC Capital Markets has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating on the stock. This adjustment reflects RBC's continued positive outlook on the company.
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results
Janux Therapeutics, Inc. (NASDAQ:JANX) missed its latest quarterly earnings expectations, with revenues significantly lower than forecasts and per-share losses exceeding predictions. As a result, analysts have reduced their revenue estimates for 2026 and increased their loss per share forecasts, though the consensus price target remains largely unchanged. Despite these adjustments, the company's projected revenue growth is still expected to be in line with the broader industry.
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating
RBC Capital has increased its price target for Janux Therapeutics (JANX) to $34 from $30, while reiterating an Outperform rating. This adjustment comes after Janux Therapeutics reported its Q2 revenue of $10.3 million, falling short of FactSet's estimate of $19.1 million. The company is a clinical-stage biopharmaceutical firm focusing on tumor-activated immunotherapies for cancer.
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results
Analysts have reduced their revenue and increased their loss per share forecasts for Janux Therapeutics (NASDAQ:JANX) after the company missed earnings in its latest quarterly results. Despite the lowered expectations, the consensus price target remains largely unchanged, suggesting that the intrinsic value of the business is perceived to be stable. The company's revenue growth is still expected to align with the industry average, but investors are advised to focus on the long-term trajectory.
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating for Janux Therapeutics Inc (JANX) with a price target of $22.00. While other analysts like William Blair also issued a Buy rating, Barclays maintained a Sell rating. The company recently reported a quarterly revenue of $3.73 million and a GAAP net loss of $24.36 million, and corporate insider sentiment is negative due to increased insider selling.
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside
Janux Therapeutics, Inc.'s average 12-month price target has been slightly reduced by analysts from $33.56 to $33.25, with a range of $14 to $60 per share. Despite the cut, the new target still implies a significant 107% potential upside based on the Aug. 6 closing price. The consensus rating for the stock remains a "Buy" among 18 covering analysts.
Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue
Janux Therapeutics reported a Q2 2026 net loss of $22.0 million, narrowing from $33.9 million a year prior, driven by $10.3 million in collaboration revenue from its Bristol-Myers Squibb agreement. For the first half of 2026, the company recorded $14.0 million in collaboration revenue and a net loss of $46.3 million. Janux maintains a strong financial position with over $1 billion in total assets as of June 30, 2026, and expects existing capital to fund operations for at least the next 12 months.
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for the second quarter of 2026, highlighting continued progress across its clinical programs, including JANX007, JANX014, and JANX011. The company maintains a strong financial position with $970.9 million in cash and investments and anticipates several key clinical milestones in late 2026 and early 2027. Net loss for the quarter was $22.0 million, an improvement from $33.9 million in the comparable period of 2025.
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) reported a Q2 loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, though it improved from a $0.55 loss a year ago. The company also missed revenue estimates, posting $10.27 million against an expectation of zero revenues a year prior. Despite this, Janux Therapeutics shares have risen 15.9% year-to-date, outperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold).
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M
Janux Therapeutics, Inc. (JANX) reported its Q2 revenue at $10.3 million, falling short of the FactSet estimate of $19.1 million. The article also mentions other recent news concerning the company, including a report of earnings results for the second quarter and six months ended June 30, 2026, and its removal from several Russell Growth Benchmarks.
BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.35
Janux Therapeutics reported a Q2 basic EPS of USD -0.35. The article, sourced from Reuters, provides this brief financial update.
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its second-quarter 2026 financial results, highlighting continued progress across its clinical portfolio. The company maintained a strong financial position with $970.9 million in cash, cash equivalents, and short-term investments, supporting the advancement of multiple clinical programs including JANX007, JANX014, and JANX011. Janux anticipates announcing initial clinical data for JANX011 and initiating clinical development for JANX013 in the second half of 2026, with further data for JANX007 expected in the first half of 2027.
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Gamble with 142% Potential Upside
Janux Therapeutics (JANX) is a clinical-stage biopharmaceutical company focusing on immunotherapies for cancer, showing a potential upside of over 142% according to analysts. Despite negative financial metrics typical of early-stage biotech firms, Janux benefits from strategic collaborations with major pharmaceutical companies and a robust clinical pipeline. The company presents a high-risk, high-reward opportunity for investors interested in innovative cancer therapies.
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com
This article reports on the filing of a Form 4 for Janux Therapeutics Inc. as of July 31st. It indicates that the filing is a standard disclosure related to insider trading or changes in ownership, as typically required by the SEC. The brief entry notes the company's stock symbol JANX and a slight dip in its price.
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com
This article announces the filing of a Form 4 for Janux Therapeutics Inc. for the period ending July 31. It provides no further details beyond this announcement and includes general market data and related news. The Form 4 filing is a mandatory SEC document reporting changes in beneficial ownership of a company's securities by insiders.
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com
This article announces the filing of Form 4 by Janux Therapeutics Inc. for July 31. It includes various market data such as indices, commodities, and shares, along with trending stocks and popular news articles from Investing.com. The piece focuses on financial updates and general market movements.
Janux Therapeutics Inc (JANX) Institutional Confidence
Janux Therapeutics Inc (JANX) has an institutional shareholding score of 10.00, ranking 1st in its industry. The institutional shareholding proportion increased by 0.64% quarter-over-quarter, reaching 110.21%. Steven Cohen is the largest institutional shareholder, though his holdings decreased by 62.25%.
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis
Janux Therapeutics Inc (JANX) currently holds a financial score of 7.85, ranking 76th out of 384 companies in the Biotechnology & Medical Research industry. The company's financial status is deemed stable, while its operating efficiency is considered average. Key financial metrics such as total revenue, operating profit, and cash flow from operating activities have not yet been disclosed by the company.
Janux Therapeutics Inc (JANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Janux Therapeutics Inc (JANX), detailing its price momentum score of 3.51 within the Biotechnology & Medical Research industry. It identifies current support at $14.46 and resistance at $16.80, suggesting suitability for range-bound swing trading. The analysis also includes specific technical indicator readings (MACD, RSI, KDJ, etc.) and moving average data, concluding with a "Neutral" signal based on these metrics.
Understanding Momentum Shifts in (JANX)
An analysis of Janux Therapeutics Inc. (NASDAQ: JANX) indicates weak sentiment across all time horizons, supporting a short bias. The article identifies a mid-channel oscillation pattern and highlights an exceptional 99.0:1 risk-reward short setup targeting a 29.8% downside. AI-generated trading strategies are provided for position trading (long), momentum breakout, and risk hedging (short).
Janux Therapeutics, Inc. Revenue Breakdown – NASDAQ:JANX
Janux Therapeutics, Inc. (NASDAQ:JANX) generated $10.00 million USD in revenue last year, primarily from its Novel Immunotherapies segment, which also contributed $10.00 million USD in revenue. The United States was its largest geographical contributor, also accounting for $10.00 million USD in revenue in the previous fiscal year. This marks a slight decrease from the $10.59 million USD generated in the prior year across both the segment and country.
Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Janux Therapeutics Inc (JANX), noting its current valuation score of 7.63, which ranks it 208 out of 384 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -8.12, comparing it to recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
BlackRock (NYSE: BLK) discloses 6.7% beneficial stake in Janux Therapeutics (JANX)
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership in Janux Therapeutics, Inc., amounting to 4,098,457 shares as of June 30, 2026. The filing indicates BlackRock holds sole voting power over 4,024,396 shares and sole dispositive power over all 4,098,457 shares. While various clients benefit from these holdings, no single client owns more than five percent of Janux's outstanding common shares.
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides information regarding Janux Therapeutics Inc (JANX) stock, focusing on its dividend and stock split history. It states that the company has not distributed any dividends over the past five years. Key financial data like market cap and current stock price are also displayed, but no specific dividend or split events are listed.
JANX|Janux Therapeutics Inc|Price:15.635|Chg%:+0.305
Janux Therapeutics Inc (JANX) has a TradingKey Stock Score of 6.70/10, indicating relatively healthy fundamentals and high growth potential, though its valuation is only considered fair. The company specializes in developing tumor-activated immunotherapies for cancer, with significant revenue and profit growth. Analysts have a positive outlook, with a significant upside space to target price, despite recent institutional selling.
Janux Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance
Janux Therapeutics Inc. (JANX) is a clinical-stage biopharmaceutical company focused on developing tumor-activated immunotherapies for cancer using its TRACTr and TRACIr platforms. The company's clinical candidates, JANX007 and JANX008, target prostate cancer and various solid tumors respectively. The article provides an overview of the company's profile, including ticker symbol, IPO date, key executives, and institutional shareholdings.
Janux Therapeutics Inc (JANX) Income Statement
This article presents the quarterly and annual income statements for Janux Therapeutics Inc. (JANX), detailing revenue, operating expenses, research and development costs, and net income figures. It provides insights into the company's financial performance and efficiency over various fiscal periods, alongside a FAQ section explaining how to interpret the income statement data.
Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W
This article is a statement of changes in beneficial ownership of securities for Director Ronald W. Barrett of Janux Therapeutics. It is identified as a Form 4 filing, which indicates a required disclosure of stock transactions by company insiders. The full content is described as a "Document" which suggests it contains detailed financial transaction data.
Avoiding Lag: Real-Time Signals in (JANX) Movement
This article provides a real-time stock analysis for Janux Therapeutics Inc. (NASDAQ: JANX), indicating near-term weak sentiment but mid-term strength within a broader long-term weak bias. It highlights specific resistance and support levels, along with three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with entry zones, targets, and stop losses. The analysis also emphasizes the exceptional risk-reward short setup targeting significant downside.
